FDA Grants Priority Review for Dupixent® (dupilumab) as Potential Treatment for Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis

Author's Avatar
Nov 06, 2018
Article's Main Image

PR Newswire